183 related articles for article (PubMed ID: 35677166)
1. The Prognostic Utility of
Li C; Yu H; Chen X; Han S; Peng S; Lei T; Yang H
Front Oncol; 2022; 12():772773. PubMed ID: 35677166
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP.
Jeon YW; O JH; Park KS; Min GJ; Park SS; Yoon JH; Eom KS; Min CK; Cho SG
Br J Haematol; 2020 Mar; 188(6):860-871. PubMed ID: 31733125
[TBL] [Abstract][Full Text] [Related]
3. Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma.
Li X; Sun X; Li J; Liu Z; Mi M; Zhu F; Wu G; Lan X; Zhang L
Cancer Med; 2019 Sep; 8(11):5012-5022. PubMed ID: 31293092
[TBL] [Abstract][Full Text] [Related]
4. Optimisation of metabolic criteria in the prognostic assessment in patients with lymphoma. A multicentre study.
Del Puig Cózar-Santiago M; García-Garzón JR; Moragas-Freixa M; Soler-Peter M; Bassa Massanas P; Sánchez-Delgado M; Sanchez-Jurado R; Aguilar-Barrios JE; Sanz-Llorens R; Ferrer-Rebolleda J
Rev Esp Med Nucl Imagen Mol; 2017; 36(5):304-311. PubMed ID: 28483373
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of the peripheral blood lymphocyte/monocyte ratio combined with
Wu W; Zhao L; Wang Y; Chen P; Yuan X; Miao L; Zhu Y; Mao J; Cai Z; Ji Y; Wang L; Jia T
Curr Probl Cancer; 2024 Feb; 48():101066. PubMed ID: 38364336
[TBL] [Abstract][Full Text] [Related]
6. Interim FDG
Duarte S; Roque A; Saraiva T; Afonso C; Marques BA; Lima CB; Neves D; Lai AC; Costa G; Cipriano A; Geraldes C; Ruzickova L; Carda JP; Gomes M
Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):e107-e116. PubMed ID: 36567213
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of metabolic tumour volume on baseline
Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
[TBL] [Abstract][Full Text] [Related]
8. Interim PET/CT in diffuse large B-cell lymphoma may facilitate identification of good-prognosis patients among IPI-stratified patients.
Nyilas R; Farkas B; Bicsko RR; Magyari F; Pinczes LI; Illes A; Gergely L
Int J Hematol; 2019 Sep; 110(3):331-339. PubMed ID: 31228077
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of
Geng H; Lian K; Zhang W
Quant Imaging Med Surg; 2024 Jan; 14(1):325-334. PubMed ID: 38223089
[TBL] [Abstract][Full Text] [Related]
10. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial.
Schmitz C; Hüttmann A; Müller SP; Hanoun M; Boellaard R; Brinkmann M; Jöckel KH; Dührsen U; Rekowski J
Eur J Cancer; 2020 Jan; 124():25-36. PubMed ID: 31710995
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of PET-CT in patients with diffuse large B-cell lymphoma].
Ding C; Li T; Sun J; Yang W; Ding Q; Xu X
Zhonghua Zhong Liu Za Zhi; 2014 Dec; 36(12):923-7. PubMed ID: 25623768
[TBL] [Abstract][Full Text] [Related]
12. [Values of Different Evaluation Criteria of Interim
Zhu LT; Cen XN; Ou JP; Qiu ZX; Wang LH; Liu W; Wang WS; Dong YJ; Liang ZY; Wang MJ; Xu WL; Sun YH; Wang Q; Yin Y; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):431-437. PubMed ID: 28446288
[TBL] [Abstract][Full Text] [Related]
13. Interim
Jiang M; Chen P; Ruan X; Ye X; Pan Y; Zhang J; Huang Q; Zhou W; Wu H; Wang Q
Oncol Lett; 2017 Dec; 14(6):6715-6723. PubMed ID: 29344120
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
[TBL] [Abstract][Full Text] [Related]
15. Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.
de Oliveira Costa R; Hallack Neto A; Siqueira S; Lage LA; de Paula HM; Coutinho AM; Pereira J
Nucl Med Commun; 2016 Oct; 37(10):1095-101. PubMed ID: 27281359
[TBL] [Abstract][Full Text] [Related]
16. Improved prediction of chemoresistance in patients with diffuse large B-cell lymphoma through a new interim positron emission tomography-computed tomography evaluation model.
Xie W; Liu MK; Jiang XF; Gao XD; Li B; Wang L; Zhao WL
Acta Oncol; 2021 Jun; 60(6):735-743. PubMed ID: 33720799
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of baseline
Zhu L; Meng Y; Guo L; Zhao H; Shi Y; Li S; Wang A; Zhang X; Shi J; Zhu J; Xu K
Oncol Lett; 2021 Feb; 21(2):132. PubMed ID: 33552253
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of whole-body dynamic
Yin J; Wang H; Zhu G; Chen N; Khan MI; Zhao Y
Heliyon; 2023 Sep; 9(9):e19749. PubMed ID: 37809527
[TBL] [Abstract][Full Text] [Related]
19. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
20. Value of
Jiang C; Teng Y; Chen J; Wang Z; Zhou Z; Ding C; Xu J
Ann Nucl Med; 2020 Dec; 34(12):911-919. PubMed ID: 33057996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
